CN109438517B - Complex of bifunctional linking agent coordinated with carbonyl metal core and preparation method thereof - Google Patents

Complex of bifunctional linking agent coordinated with carbonyl metal core and preparation method thereof Download PDF

Info

Publication number
CN109438517B
CN109438517B CN201811611294.6A CN201811611294A CN109438517B CN 109438517 B CN109438517 B CN 109438517B CN 201811611294 A CN201811611294 A CN 201811611294A CN 109438517 B CN109438517 B CN 109438517B
Authority
CN
China
Prior art keywords
bis
hydroxy
solution
ethylenediamine
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811611294.6A
Other languages
Chinese (zh)
Other versions
CN109438517A (en
Inventor
朱霖
时圣寓
查智豪
孔繁渊
郎红梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Jiujie Contamination Control Technology Co ltd
Original Assignee
Beijing Jiujie Contamination Control Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Jiujie Contamination Control Technology Co ltd filed Critical Beijing Jiujie Contamination Control Technology Co ltd
Priority to CN201811611294.6A priority Critical patent/CN109438517B/en
Publication of CN109438517A publication Critical patent/CN109438517A/en
Application granted granted Critical
Publication of CN109438517B publication Critical patent/CN109438517B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic System
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

The invention relates to a complex of a bifunctional linking agent coordinated with a carbonyl metal core and a preparation method thereof, belonging to the technical field of radiopharmaceutical chemistry; the bifunctional linking agent is N, N' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl]ethylenediamine-N, N' -diacetic acid, which has the following structural formula:
Figure DDA0001924803000000011
wherein, R is1And R2At least one of the two is targeting small molecule or polypeptide or protein macromolecule, and the metal is technetium or rhenium. The invention successfully obtains the HBED-CC complex labeled by the technetium carbonyl/rhenium core for the first time, and thus realizes different nuclides (i.e., (ii) of the same labeled precursor68Ga、99mTc/Re) targeting the same targetThe two imaging modes (PET/SPECT) complement each other,188/186the Re complex can be used for research of radioactive therapeutic drugs. Provides a new idea for the development of Tc-99m single-photon radioactive tracers and Re-188/186 radiotherapy medicaments, and also widens the application range of HBED-CC derivatives as radiopharmaceutical labeled precursors.

Description

Complex of bifunctional linking agent coordinated with carbonyl metal core and preparation method thereof
Technical Field
The invention relates to a complex of a bifunctional linker coordinated with a carbonyl metal core and a preparation method thereof, in particular to a complex of a bifunctional linker labeled with a carbonyl technetium/rhenium core and a preparation method thereof, belonging to the technical field of radiopharmaceutical chemistry.
Background
Molecular nuclear medicine utilizes radionuclide tracing technology to recognize diseases from molecular level, elucidates the mechanisms of blood flow, metabolism, receptor density and function change, gene abnormal expression, biochemical metabolism change, cell information conduction and the like of target organs or tissues, provides relevant information on molecular level for early diagnosis, curative effect evaluation and basic research of diseases, is a leading-edge and hot topic of the research in the world medical field at present, and is a pursuit target of modern molecular medicine. Therefore, it is an important component of molecular imaging and an important marker for the development of modern medical imaging. The core technology of molecular nuclear medicine is the design and development of highly specific molecular probes, i.e., imaging agents (imaging drugs), which are important factors that restrict the development of nuclear medicine.
The most commonly used nuclear medicine molecular imaging techniques at present are PET/CT (positron emission tomography) and SPECT/CT (single photon emission computed tomography). The most widely used PET imaging agent is18F-deoxyglucose (FDG), which has a wide range of applications in the diagnosis and monitoring of cancer progression. But in the last decade, with68Ge/68Commercialization of Ga generators, positron emitting radionuclides Ga-68 (t)1/2＝68min，β+511keV) has becomeThe new hot nuclide for PET imaging drug research, namely the nuclide of Ga-68, has convenient source and relatively low cost, and does not need a cyclotron. The molecular probe labeled by the metal radionuclide is formed by connecting a targeting group molecule and a radioactive metal nuclide through a bifunctional linker to form a targeting stable metal complex, as shown in figure 8. 2016 (long), and68Ga]Ga-DOTA-TATE has been approved by the FDA for the diagnosis of neuroendocrine tumors, and this fact fully represents the importance of metal complexes in various clinical applications.
N, N '-bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N' -diacetic acid (HBED-CC) is a commonly used bifunctional linker in the preparation of Ga-68 labeled radiopharmaceuticals. The Ga-68 can be used for carrying out rapid and effective radioactive labeling on the HBED-CC and the derivatives thereof at room temperature, and the label has high in-vivo stability.
In recent years, a tumor imaging agent taking prostate specific membrane antigen as target68Ga-PSMA-11 has received a great deal of worldwide attention due to its excellent biological properties. (Afshhar-Oromieh et al, Eur J Nucl Med Mol Imaging (2017)44: 1258-1268) the bifunctional linker used in the molecular structure of this radiotracer is HBED-CC.
Subsequently, HBED-CC has rapidly developed as a bifunctional linker labeling Ga-68 drugs, such as:68Ga-HBED-CC-CAA(Zha Z,Song J,Choi S R,et al.Bioconjug Chem,2016,27(5):1314-1323)、68Ga-HBED-CC-Tetrafluorophenolate(Eder M,et al.European Journal of Nuclear Medicine&Molecular Imaging,2008,35(10):1878-1886)、68Ga-HBED-CC-PEG-scVEGF(Eder M,Krivoshein AV,Backer M,et al.Nuclear Medicine&Biology,2010,37(4):405-412)、68Ga-HBED-CC-PCA(Trencsényi G,Dénes N,Nagy G,et al.Journal of Pharmaceutical&Biomedical Analysis,2017,139:54-64)、68Ga-HBED-CC-EDBE-folate(Choi P S,Lee J Y,Park J H,et al.Journal of Labelled Compounds&Radiopharmaceuticals,2018,61(1),4-10)、68Ga-HBED-CC-c(NGR)、68Ga-HBED-CC-c(RGD)(Satpati D,Sharma R,Sarma H D,et al.Chemical Biology&Drug Design,2017，8(3),673-679)、68Ga-HBED-CC-AE105(Vats K,Sharma R,Sarma H D,et al.Anticancer Agents Med Chem,2018,18.)。
Tc-99m(t1/26h, gamma-140 keV) labeled single photon radioactive tracer has been applied to clinical SPECT imaging for over 40 years, and has important application value in a plurality of research fields such as early diagnosis and cancer stage of tumors, brain serious diseases such as Alzheimer's disease, myocardial function, renal function and the like. Its use cost is much more economical than PET/CT. In China, the PET/CT technology is mainly applied to various major cities at present, and according to statistics, the number of PET instruments in the whole country is about 300. The SPECT/CT technology is widely applied to most of two-three-line cities in China, and according to statistics, the number of SPECT instruments in the whole country is about 800.
Among the technetium-99 m radiopharmaceuticals commonly used in clinical practice, the technetium-99 m has the common valence states +5, +3 and + 1. +5 valent technetium-99 m may form TcO, TcO2、TcN(K.E.Baidoo and S.Z.Lever,Bioconjugate chemistry,1990,1,132.C.J.Smith,N.Li,K.V.Katti,C.Higginbotham and W.A.Volkert,Nuclear Medicine&Biology,1997,24, 685-. Such as brain perfusion imaging agents99mTc-D, L-HMPAO and bone imaging agents99mTc-MDP, which is used for millions of clinical scans each year worldwide. TcN the core of the labeling compound uses coordinating atoms that are predominantly S or P atoms. The common structural core of + 3-valent technetium-99 m is [ Tc (NS)3)[(*CNR)](H.Spies, M.Glaser, H.J.Pietzsch, F.E.Hahn and T.L ü gger, Inorganica Chimica Acta,1995,240,465 and 478.). The common structural core of the +1 valent technetium-99 m is technetium carbonyl ([ Tc (CO))3]+) The core can coordinate with a coordination atom such as N, O, S, and a common ligand is a N, O, S-containing small molecule.
So far, many researchers have conducted many researches on labeling metal technetium by HBED-CC, but most of them focus on TcO core to label HBED-CC, and none of them are successful; furthermore, due to the complex structure of HBED-CC, it is widely recognized by those skilled in the art that it is not suitable for core labeling of technetium carbonyl.
The present inventors have attempted to label HBED-CC with a technetium carbonyl core, and have unexpectedly found that HBED-CC can be labeled with technetium carbonyl by adjusting the reaction conditions and group substitution, and that HBED-CC can also be labeled with rhenium carbonyl.
Disclosure of Invention
One of the objects of the present invention is to provide a complex of a bifunctional linker coordinated to a metal carbonyl core, which is simple to prepare and has the potential to become a superior SPECT imaging agent.
In order to achieve the purpose, the invention adopts the following technical scheme:
a complex of a bifunctional linker coordinated to a metal carbonyl core, characterized in that: the bifunctional linking agent is N, N '-bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N' -diacetic acid, and the structural formula is as follows:
Figure BDA0001924802980000031
wherein, R is1And R2At least one is a targeting small molecule or polypeptide.
Preferably, the metal is technetium and its isotope(s) (ii)99mTc) or rhenium and isotopes thereof (188/186Re)。
Preferably, the targeting small molecule or polypeptide is mAb425, Cys-tagged vascular endothelial growth factor (ScVEGF), glu-urea-lysine (PSMA targeting group), procainamide (procainamide), 4-amino-N- (2-diethylaminoethyl) benzamide (PCA, 4-amino-N- (2-diazepamine) benzamide), folic acid (folate), pegylated Styrylpyridine Conjugates (pegylated Styrylpyridine Conjugates), Asparagine-glycine-arginine (NGR, Asparagine-glycine-arginine), arginine-glycine-aspartic acid (RGD, arginine-glycine-aspartic acid), and derivatives thereof.
Preferably, said R is1＝OH，
Figure BDA0001924802980000041
Preferably, the
Figure BDA0001924802980000042
Preferably, the
Figure BDA0001924802980000043
Preferably, the
Figure BDA0001924802980000044
Figure BDA0001924802980000045
Another object of the present invention is to provide a method for preparing a complex of a bifunctional linker coordinated to a metal carbonyl core that is simple and has the potential to be a superior SPECT imaging agent.
Technical solution 1
A preparation method of a coordination compound of a carbonyl technetium core marked bifunctional linker comprises the following steps:
(1) preparation of N, N '-bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N' -diacetic acid containing substituent groups
Adding BF to methanol solution of 3- (4-hydroxyphenyl) propionic acid3·Et2O, stirring at room temperature, removing the solvent, and purifying by flash chromatography to obtain a methylated product, namely methyl 3- (4-hydroxyphenyl) propionate;
adding MgCl into 3- (4-hydroxyphenyl) methyl propionate in acetonitrile2Paraformaldehyde and triethylamine, heating the mixture to reflux, diluting with water, and diluting with waterAcidifying with hydrochloric acid, extracting with diethyl ether, and separating the organic layer with MgSO4Drying and filtering, concentrating the filtrate, and purifying the residue by flash chromatography to give methyl 3- (3-formyl-4-hydroxyphenyl) propionate;
adding ethylenediamine into 3- (3-formyl-4-hydroxyphenyl) methyl propionate dissolved in MeOH at room temperature, stirring overnight at 50 ℃, cooling the bis-Schiff base obtained by condensation reaction in ice bath, and adding NaBH in batches4And stirred at room temperature overnight, the mixture was extracted with ethyl acetate, and the organic layer was then extracted with MgSO4Drying, filtering, concentrating the filtrate and purifying the resulting residue by flash chromatography to obtain 3,3' - ((ethane-1, 2-diylbis (azenediyl)) bis-dimethyl (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate;
to a solution of 3,3' - ((ethane-1, 2-diylbis (azenediyl)) bis-dimethyl (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate in acetonitrile was added tert-butyl bromoacetate and Na2CO3Then the mixture is heated at 60 ℃, overnight, cooled to room temperature and filtered, the filtrate is concentrated and the residue is purified by flash chromatography to give 3,3' - (((2,2,13, 13-tetramethyl-4, 11-dioxo-3, 12-) dimethyldioxa-6, 9-diazatetetradecane-6, 9-diyl) di (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate;
a methanol/sodium hydroxide (1N) (1/1) solution of 3,3' - (((2,2,13, 13-tetramethyl-4, 11-dioxo-3, 12-) dimethyldioxa-6, 9-diazatetradecane-6, 9-diyl) di (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate was stirred at room temperature to remove the methyl group, then hydrochloric acid was added to the reaction mixture to adjust the pH to 4-5, the resulting mixture was extracted with EtOAc, and then the organic layer was extracted with MgSO 44Drying and filtering, concentrating the filtrate to obtain a residue which is purified by flash chromatography to obtain 3,3' - ((((2, 2,13, 13-tetramethyl-4, 11-dioxo-3, 12-dioxa-6, 9-diazacyclotetradecane-6, 9-diyl) di (methylene)) di (4-hydroxy-3, 1-phenylene)) dipropionate;
then, N ' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N ' -diacetic acid containing a substituent group was prepared separately from 3,3' - ((((2, 2,13,13 tetramethyl-4, 11-dioxo-3, 12-dioxa-6, 9-diazacyclotetradecane-6, 9-diyl) di (methylene)) di (4-hydroxy-3, 1-phenylene)) dipropionate;
(2)[99mTc][Tc(CO)3(H2O)3]+preparation of intermediate solutions
The reaction ratio of Na2CO3，NaBH4And sodium potassium tartrate are dissolved in the brine, CO gas is introduced, and then an appropriate amount of [ alpha ], [ alpha ] is added99mTc]NaTcO4The physiological saline solution of (1), reacting the mixture at 60 to 90 ℃, cooling to room temperature, and then acidifying the solution to pH 7 to 8 to obtain the product99mTc][Tc(CO)3(H2O)3]+An intermediate solution;
(3) preparation of complex of carbonyl technetium core marked bifunctional linker
To the [2 ] prepared in step (2)99mTc][Tc(CO)3(H2O)3]+Respectively adding proper amount of the N, N' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl containing substituent groups prepared in the step (1) into the intermediate solution]ethylenediamine-N, N' -diacetic acid (dissolved in 1ml of 0.05M sodium acetate solution at pH 5) and the reaction mixture was heated to obtain a complex of the carbonyl technetium core-labeled bifunctional linker.
Technical solution 2
A method for preparing a complex of a carbonyl rhenium core labeled bifunctional linker comprises the following steps:
(1) preparation of N, N '-bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N' -diacetic acid containing substituent groups
Adding BF to methanol solution of 3- (4-hydroxyphenyl) propionic acid3·Et2O, stirring at room temperature, removing the solvent, and purifying by flash chromatography to obtain a methylated product, namely methyl 3- (4-hydroxyphenyl) propionate;
adding MgCl into 3- (4-hydroxyphenyl) methyl propionate in acetonitrile2Paraformaldehyde and triethylamine, heating and refluxing the mixture, diluting with water, acidifying with hydrochloric acid, extracting with diethyl ether, and collecting the organic layer with MgSO4Drying and filtering, concentrating the filtrate, andpurifying the residue by flash chromatography to give methyl 3- (3-formyl-4-hydroxyphenyl) propionate;
adding ethylenediamine into 3- (3-formyl-4-hydroxyphenyl) methyl propionate dissolved in MeOH at room temperature, stirring overnight at 50 ℃, cooling the bis-Schiff base obtained by condensation reaction in ice bath, and adding NaBH in batches4And stirred at room temperature overnight, the mixture was extracted with ethyl acetate, and the organic layer was then extracted with MgSO4Drying, filtering, concentrating the filtrate and purifying the resulting residue by flash chromatography to obtain 3,3' - ((ethane-1, 2-diylbis (azenediyl)) bis-dimethyl (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate;
to a solution of 3,3' - ((ethane-1, 2-diylbis (azenediyl)) bis-dimethyl (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate in acetonitrile was added tert-butyl bromoacetate and Na2CO3Then the mixture is heated at 60 ℃, overnight, cooled to room temperature and filtered, the filtrate is concentrated and the residue is purified by flash chromatography to give 3,3' - (((2,2,13, 13-tetramethyl-4, 11-dioxo-3, 12-) dimethyldioxa-6, 9-diazatetetradecane-6, 9-diyl) di (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate;
a methanol/sodium hydroxide (1N) (1/1) solution of 3,3' - (((2,2,13, 13-tetramethyl-4, 11-dioxo-3, 12-) dimethyldioxa-6, 9-diazatetradecane-6, 9-diyl) di (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate was stirred at room temperature to remove the methyl group, then hydrochloric acid was added to the reaction mixture to adjust the pH to 4-5, the resulting mixture was extracted with EtOAc, and then the organic layer was extracted with MgSO 44Drying and filtering, concentrating the filtrate to obtain a residue which is purified by flash chromatography to obtain 3,3' - ((((2, 2,13, 13-tetramethyl-4, 11-dioxo-3, 12-dioxa-6, 9-diazacyclotetradecane-6, 9-diyl) di (methylene)) di (4-hydroxy-3, 1-phenylene)) dipropionate;
then, N ' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N ' -diacetic acid containing a substituent group was prepared separately from 3,3' - ((((2, 2,13,13 tetramethyl-4, 11-dioxo-3, 12-dioxa-6, 9-diazacyclotetradecane-6, 9-diyl) di (methylene)) di (4-hydroxy-3, 1-phenylene)) dipropionate;
(2) preparation of carbonyl rhenium core marking complex of N, N '-bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N' -diacetic acid containing substituent group
Refluxing under water solution of rhenium pentacarbonyl bromide, and then carrying out the N, N' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl group containing the substituent group prepared in the step (1)]ethylenediamine-N, N' -diacetic acid to a solution containing Re (CO)3(H2O)3In the reaction solution of the Br intermediate, the mixture was acidified to pH 4 to 6, and heated to obtain N, N' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl group having a substituent group]Carbonyl rhenium core labeling complex of ethylenediamine-N, N' -diacetic acid.
Preferably, the structure of the substituted group-containing N, N '-bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N' -diacetic acid in the step (1) is as follows:
Figure BDA0001924802980000071
wherein, R is1And R2At least one of them is a targeting small molecule or polypeptide or protein.
Preferably, the targeting small molecule or polypeptide is mAb425, Cys-tagged vascular endothelial growth factor (ScVEGF), glu-urea-lysine, procainamide (procainamide), 4-amino-N- (2-diethylaminoethyl) benzamide (PCA, 4-amino-N- (2-diethylaminoethyl) benzamide), folic acid (folate), pegylated Styrylpyridine Conjugates (RGD), Asparagine-glycine-arginine (Asparagine-glycine-arginine), arginine-glycine-aspartic acid (RGD), and derivatives thereof.
Preferably, the
Figure BDA0001924802980000081
Preferably, the
Figure BDA0001924802980000082
Preferably, the
Figure BDA0001924802980000083
Figure BDA0001924802980000084
Preferably, the acidification in step (2) is with hydrochloric acid.
Preferably, the concentration of the hydrochloric acid in the step (2) is 0.05 mol/L.
Preferably, the heating temperature in the step (3) is 95 ℃ and the time is 30 minutes.
Has the advantages that:
the present invention first utilizes99mTc][Tc/Re(CO)3(H2O)3]+The HBED-CC derivative with good biological properties is subjected to radioactive labeling, and the inventor finds that N, N' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl group containing substituent]ethylenediamine-N, N' -diacetic acid can realize the labeling of technetium carbonyl or rhenium; and, N' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl group having a disubstituted group]The ethylenediamine-N, N' -diacetic acid is coordinated with the Tc-99m/Re carbonyl technetium/rhenium core marker, and the effect is particularly good; thus achieving different species for the same label precursor68Ga、99mTc/Re), and the mutual complementation of two imaging modes (PET/SPECT) is expected to be realized aiming at the same target point; provides a new idea for the development of Tc-99m single-photon radioactive tracers, and also widens the application range of HBED-CC derivatives as radioactive drug labeling precursors. In addition, the ligand capable of coordinating with Tc can also coordinate with the same family element Re, and Re-186 and Re-188 are therapeutic nuclides which are widely applied clinically at present. Thus, Re (CO) in the present invention3the-HBED-CC derivative can also be developed as a therapeutic drug, thereby realizing the real diagnosis and treatment integration.
The invention is further illustrated by the following figures and detailed description of the invention, which are not meant to limit the scope of the invention.
Drawings
FIG. 1 is the [2 ] prepared in example 1 of the present invention99mTc]Tc(CO)3-L2Radioactive liquid chromatography analysis of (1).
FIG. 2 is the value of [2 ] prepared in example 2 of the present invention99mTc]Tc(CO)3-L3Radioactive liquid chromatography analysis chart of
FIG. 3 shows Re (CO) prepared in example 3 of the present invention3-L2Ultraviolet liquid chromatography analysis chart of (1).
FIG. 4 shows Re (CO) prepared in example 4 of the present invention3-L3Ultraviolet liquid chromatography analysis chart of the complex.
FIG. 5 is the [2 ] prepared in example 5 of the present invention99mTc]Tc(CO)3-L4Radioactive liquid chromatography analysis of the complex.
FIG. 6 is the value of [2 ] prepared in example 6 of the present invention99mTc]Tc(CO)3-L1Radioactive liquid chromatography analysis of the complex.
FIG. 7 the [2 ] prepared in example 7 of the present invention99mTc]Tc(CO)3-radioactive liquid chromatography profile of PSMA-11 complex.
FIG. 8 shows a targeting stable metal complex of Ga-68.
The specific implementation mode is as follows:
the following is N, N' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl]The structural formula of each compound in the preparation process of ethylenediamine-N, N '-diacetic acid and derivatives thereof is shown in the specification, wherein the compound 1 is HBED-CC, and the compound 2 is 2,2' - (ethane-1, 2-diyl bis ((2-hydroxy-5- (3- ((2- (2-nitro-1H-imidazol-1-yl) ethyl) amino) -3-oxopropyl) benzyl) -azepindiyl)) diacetic acid (L)2) Compound 3 is methyl 3- (4-hydroxyphenyl) propionate, compound 4 is methyl 3- (3-formyl-4-hydroxyphenyl) propionate, compound 5 is 3,3'- (((ethane-1, 2-diylbis (azepindiyl)) bis-dimethyl (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate, compound 6 is 3,3' - ((2,2,13, 13-tetramethyl-4, 11-dioxo-3, 12-) dimethylbis (dipropionate)Oxa-6, 9-diazatetetradecane-6, 9-diyl) di (methylene)) di (4-hydroxy-3, 1-phenylene)) dipropionate, compound 7 is 3,3' - ((((2, 2,13, 13-tetramethyl-4, 11-dioxo-3, 12-dioxa-6, 9-diazatetetradecane-6, 9-diyl) di (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate, compound 8 is 2,2' - (ethane-1, 2-diyl bis ((2-hydroxy-5- (3- ((2- (2-nitro-1H-imidazol-1-yl) ethyl) amino) -3-oxopropyl) benzyl) -azepindiyl)) diacetic acid.
Figure BDA0001924802980000101
Unless otherwise specified, reagents and raw materials used in the preparation methods and detection methods described in the following examples and comparative examples are commercially available, and all the equipment used are conventional equipment.
Example 1
99mTc(CO)3-L2Preparation of the complex:
(1) ligand L2Synthesis of (2)
Synthesis of Compound 3 (methyl 3- (4-hydroxyphenyl) propionate): after p-hydroxyphenylpropionic acid (3g, 18.1mmol) and 50mL of methanol were charged in a round-bottom flask, and boron trifluoride diethyl etherate (0.3mL) was then added dropwise to the mixed solution, and stirred at room temperature for 6 hours, the organic phase in the filtrate was removed under reduced pressure using a rotary evaporator, separated by a silica gel column using n-hexane/ethyl acetate (v/v, 2/8), the objective component was collected, and the solvent was removed under reduced pressure to obtain 2.72g of a white solid (yield: 84%);
1HNMR(400MHz,CDCl3) δ 7.07(d,2H, J ═ 8.4Hz),6.76(d,2H, J ═ 8.4Hz),4.72(s,1H),3.68(s,3H),2.89(t,2H, J ═ 7.6Hz),2.60(t,2H, J ═ 7.6 Hz); HRMS (ESI) theoretical molecular weight C10H13O3(M+H)+181.0865; measured molecular weight, 181.0815;
synthesis of Compound 4 (methyl 3- (3-formyl-4-hydroxyphenyl) propionate): a round-bottomed flask was charged with Compound 3(2.72g, 15.1mmol), magnesium sulfate (2.87g, 30.2mmol), triethylamine (6.1g, 60.4mmol), and poly (N-ethyl-L-methyl-L-propylamine)Formaldehyde (3.66g, 120.8mmol) and 70mL of anhydrous acetonitrile were refluxed for 8 hours, heated to room temperature, added with 25mL of water and 100mL of hydrochloric acid solution (5%), the aqueous phase was extracted with diethyl ether 3 times (50 mL. times.3), the organic phases were combined, dried over anhydrous magnesium sulfate, filtered to remove solid impurities, the organic phase in the filtrate was removed under reduced pressure using a rotary evaporator, the filtrate was subjected to silica gel column separation using n-hexane/ethyl acetate (v/v, 2/8), the objective fraction was collected, and the solvent was removed under reduced pressure to give 2.85g of a white solid L2(yield: 90%);
1HNMR(400MHz,CDCl3) δ 10.89(s,1H),9.88(s,1H),7.37-7.40(m,2H),6.94(d,1H, J ═ 9.6Hz),3.68(s,3H),2.95(t,2H, J ═ 7.4Hz),2.64(t,2H, J ═ 7.4 Hz); HRMS (ESI) theoretical molecular weight C11H13O4(M+H)+209.0814; measured molecular weight, 209.0825;
synthesis of compound 5(3,3' - (((ethane-1, 2-diylbis (azenediyl)) bis-dimethyl (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate): dissolving compound 4(2.84g, 13.6mmol) in 60mL of methanol, adding ethylenediamine (0.371g, 6.18mmol) dropwise to the mixed solution, heating at 50 ℃ under reflux overnight, then cooling to 0 ℃ with an ice-water bath, adding sodium borohydride (1.05g, 27.81mmol) in 3 batches to the reaction solution, slowly raising to room temperature, after 24 hours of reaction, adding 100mL of water to terminate the reaction, extracting the aqueous phase 3 times with ethyl acetate (150 mL. times.3), combining the organic phases, drying with anhydrous magnesium sulfate, filtering to remove solid impurities, removing the organic phase from the filtrate under reduced pressure with a rotary evaporator, separating with a silica gel column using dichloromethane/ethanol/aqueous ammonia (v/v/v, 90/9/1), collecting the target component, removing the solvent under reduced pressure, 2.08g of colorless oil (yield: 69%);
1HNMR(400MHz,CDCl3) δ 7.00(dd,2H, J ═ 2.0Hz, J ═ 8.4Hz),6.82(d,2H, J ═ 2.0Hz),6.76(d,2H, J ═ 8.4Hz),3.97(s,4H),2.67(s,6H),2.83-2.87(m,8H),2.58(t,4H, J ═ 7.8 Hz); HRMS (ESI) theoretical molecular weight C24H33N2O6(M+H)+445.2339; measured molecular weight, 445.2139;
synthesis of Compound 6(3,3' - ((((2, 2,13, 13-tetramethyl-4, 11-dioxo-3, 12-) dimethyldioxa-6, 9-diazatetradecane-6, 9-diyl) di (methylene)) di (4-hydroxy-3, 1-phenylene)) dipropionate): compound 5(1.8g, 4.05mmol), tert-butyl bromoacetate (1.66g, 8.51mmol), sodium carbonate (1.71g, 16.2mmol) and 50mL of acetonitrile were added to a round-bottom flask, stirred at 60 ℃ overnight, cooled to room temperature, filtered to remove solid impurities, the organic phase in the filtrate was removed under reduced pressure using a rotary evaporator, separated on a silica gel column with n-hexane/ethyl acetate (v/v, 1/1), the desired fraction was collected and the solvent was removed under reduced pressure to give 2.36g of a colorless oil (yield: 87%);
1HNMR(400MHz,CDCl3) δ 9.55(s,2H),7.00(dd,2H, J ═ 2.0Hz, J ═ 8.4Hz),6.77(d,2H, J ═ 8.4Hz),6.74(d,2H, J ═ 2.0Hz),3.70(s,4H),3.67(s,6H),3.17(s,4H),2.83(t,4H, J ═ 7.8Hz),2.69(s,4H),2.57(t,4H, J ═ 7.8Hz),1.46(s, 18H); HRMS (ESI) theoretical molecular weight C36H53N2O10(M+H)+673.3700; measured molecular weight, 673.3662;
synthesis of Compound 7(3,3' - (((2,2,13,13 tetramethyl-4, 11-dioxo-3, 12-dioxa-6, 9-diazatetradecane-6, 9-diyl) di (methylene)) di (4-hydroxy-3, 1-phenylene)) dipropionate): adding compound 6(1.6g, 2.38mmol), 5mL of methanol and 5mL of sodium hydroxide solution (1N) into a round-bottomed flask, stirring at room temperature for 2 hours, cooling by means of an ice-water bath, adding hydrochloric acid solution (1N) to the reaction solution to a pH of 4-5, extracting the aqueous phase 3 times with ethyl acetate (50 mL. times.3), combining the organic phases, drying with anhydrous magnesium sulfate, filtering to remove solid impurities, removing the organic phase from the filtrate under reduced pressure by means of a rotary evaporator, filtering to remove the solid impurities, removing the organic phase from the filtrate under reduced pressure by means of a rotary evaporator, separating with a silica gel column using dichloromethane/ethanol/aqueous ammonia (v/v/v, 90/9/1), collecting the objective component, and removing the solvent under reduced pressure to obtain 1.2g of a white solid (yield: 78%);
1HNMR(400MHz,CDCl3) δ 7.03(dd,2H, J ═ 2.0Hz, J ═ 8.4Hz),6.80(d,2H, J ═ 8.4Hz),6.71(d,2H, J ═ 2.0Hz),3.56(s,4H),3.26(s,4H),2.84(t,4H, J ═ 7.0Hz),2.62(t,4H, J ═ 7.0Hz),2.56(s,4H),1.48(s, 18H); HRMS (ESI) theoretical molecular weight C34H49N2O10(M+H)+645.3387; measured molecular weight, 645.3417;
synthesis of compound 8(2,2' - (ethane-1, 2-diyl bis ((2-hydroxy-5- (3- ((2- (2-nitro-1H-imidazol-1-yl) ethyl) amino) -3-oxopropyl) benzyl) -azepindiyl)) diacetic acid): to a round bottom flask was added compound 7(433.8mg, 0.673mmol), N, N-diisopropylethylamine (DIPEA, 1.04g, 8mmol), 1-hydroxybenzotriazole hydrate (HOBt, 2mmol, 270mg), N- (3-dimethylaminopropyl) -N-ethylcarbodiimide hydrochloride (EDC, 381mg, 2mmol), 2- (2-nitro-1H-imidazol-1-yl) ethan-1-amine (235mg, 1.345mmol) and 10mL DMF, the mixture was stirred at room temperature for 4 hours, 30mL ethyl acetate was added to the reaction mixture, then the mixture was washed with water (10 mL. times.2) and brine (10mL), MgSO 2 was added4Drying and filtering, removing the organic phase in the filtrate under reduced pressure by using a rotary evaporator, filtering to remove solid impurities, removing the organic phase in the filtrate under reduced pressure by using a rotary evaporator, separating by using a silica gel column with dichloromethane/ethanol/ammonia water (v/v/v, 90/9/1), collecting the objective component, and removing the solvent under reduced pressure to obtain 1.2g of a white solid (yield: 78%);
1h NMR (400MHz, CDCl3) delta: 9.54(s, 2H), 7.02-7.00(m, 2H), 6.80(s, 2H), 6.71(t, 6H, J ═ 11.2), 6.58(s, 2H), 4.49(t, 4H, J ═ 11.0), 3.64-3.60(m, 8H), 4.21(s, 4H), 2.85(t, 4H, J ═ 14.1), 2.66(s, 4H), 2.48(t, 4H, J ═ 14.1), 1.47(s, 18H); LRMS calculates C44H60N10O12(M+H)+920.4, found 920.4;
ligand L2The synthesis of (2): compound 8(375mg, 0.408mmol) was dissolved in 10mL TFA, stirred at room temperature for 4 hours, the solvent removed under reduced pressure, and the residue purified by preparative HPLC to give 197mg of compound 2 (L) as a white solid2) (yield: 59.8%);
1H NMR(400MHz，D2O)δ：7.11(d，2H，J＝1.2)，7.08-7.06(m，4H)，7.04(d，2H，J＝1.2)，6.81(d，2H，J＝8.8)，4.52(t，4H，J＝5.8)，4.10(s，4H)，3.67(s4H), 3.60(t, 4H, J ═ 5.6), 3.51-3.46(m, 4H),2, 77(t, 4H, J ═ 7.4), 2.394(t, 4H, J ═ 7.4); LRMS calculates C36H 44N 10O 12(M+H)+809.3, found 809.3;
(2)[99mTc][Tc(CO)3(H2O)3]+preparation of intermediate solutions
4mg of Na2CO35.6mg of NaBH4And 20mg of potassium sodium tartrate were dissolved in 1mL of physiological saline, and CO gas was introduced for 15 minutes, followed by addition of an appropriate amount of [ alpha ], [ beta ] -potassium sodium tartrate99mTc]NaTcO4The physiological saline solution of (1), the mixture is reacted at 80 ℃ for 30 minutes, cooled to room temperature, and then the solution is acidified with 0.05mol/L HCl to pH 7-8 to give a solution99mTc][Tc(CO)3(H2O)3]+An intermediate solution;
(3)[99mTc]Tc(CO)3-L2preparation of the Complex
To the [2 ] prepared in step (2)99mTc][Tc(CO)3(H2O)3]+1mg of L prepared in step (1) was added to the solution2(dissolved in 1ml of a 0.05M sodium acetate solution having a pH of 5), and the reaction mixture was heated at 95 ℃ for 30 minutes to give [ alpha ], [ solution ] of sodium acetate99mTc]Tc(CO)3-L2A complex, whose possible structural formula is as follows:
Figure BDA0001924802980000131
as shown in FIG. 1, is the product of the present invention prepared in example 199mTc]Tc(CO)3-L2The analysis result shows that: the product had only one structure and a retention time of 13.7 minutes; the radiochemical purity is greater than 95%. The existence of a split peak indicates the existence of chiral isomers in the complex structure.
The radiochemical purity of the product is more than 95 percent.
Example 2
99mTc(CO)3-L3Preparation of the complex:
(1) ligand L3Preparation of
1) Dual activated (HBED-CC) TFP2The synthesis of (2):
from the compound 1(N, N' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl]ethylenediamine-N, N' -diacetic acid) as a reaction starting material, mixing and stirring the compound 1 and ferric chloride at room temperature for 20 minutes according to an equivalent of 1:1.1, and purifying the product by flash chromatography to obtain [ Fe (HBEDCC)]–(ii) a To 1000. mu.L of [ Fe (HBED-CC) at a concentration of 0.01M]–Adding 10 equivalents of TFP (trifluoropyrazine) and 4 equivalents of N, N' -diisopropylcarbodiimide, reacting at room temperature for 3 days, and purifying the product by preparative HPLC to obtain [ Fe (HBED-CC)]TFP2Diluting with water, and mixing the diluted [ Fe (HBED-CC) ]]TFP2The solution was injected onto a RP18 column, and the RP18 filter column was washed with 3mL, 1M HCl and 4mL H2O washing to remove complexed Fe3 +Residual (HBED-CC) TFP2Eluted with 2mL of acetonitrile and evaporated to dryness to give bis-activated (HBED-CC) TFP2And actually measuring mass spectrum: 830.0[ M + H ] M/z]+；C32H33F4N2O10829.7;
2) preparation of tert-butyl protected glutamic acid-urea-lysine:
in the presence of triphosgene (1 equivalent, 1mmol) in CH2Cl2(150mL) of the solution was added tert-butyl protected glutamic acid 9(3 equiv.) and DIPEA (3.0mL) to give tert-butyl protected glutamic acid isocyanate 10; then, allyloxycarbonyl-protected lysine (amino group of the amino acid is immobilized by 2-chloro-trityl resin (Merck, Darmstadt, germany) and commercially available) was added to the mixed solution and reacted with stirring at room temperature for 16 hours to obtain a product 11; the 2-chloro-trityl resin was filtered off, the allyloxycarbonyl protecting group cleaved on the resin, and the coupling of the amino group with hexanoic acid was then performed using fluorenylmethoxycarbonyl (Fmoc) -protected 6-aminocaproic acid (Sigma-Aldrich, Germany) to give product 12 in CH2Cl2The product 12 is prepared from 30% 1,1,1,3,3, 3-hexafluoroisopropanolThe resin was cleaved and purified by chromatography on a Chromolith RP-18e column (100X 10 mm; Merck, Darmstadt, Germany) eluting with a gradient of solvent A (consisting of 0.1% aqueous TFA) and solvent B (0.1% TFA in acetonitrile) starting from 0% B and rising to 60% B in 6 minutes and then increasing to 100% B in 1 minute at a flow rate of 6mL/min to give product 13.
Figure BDA0001924802980000141
Bis-activated (HBED-CC) TFP in 2.4 equivalents of DIPEA (N, N-diisopropylethylamine) in DMF (N, N-dimethylformamide)2With 2.4 equivalents of t-butyl protected glutamic-urea-lysine; after HPLC purification, product 13 was hydrolyzed using TFA and after 1 hour of reaction the mixture was purified by HPLC to give L3The structure is as follows, and the yield is 29%;
Figure BDA0001924802980000151
purity > 98% by analytical HPLC analysis, molecular weight determined by mass spectrometry, calculated 1361.6, actual 1361.6;
(2)[99mTc][Tc(CO)3(H2O)3]+preparation of intermediate solutions
4mg of Na2CO35.6mg of NaBH4And 20mg of potassium sodium tartrate were dissolved in 1mL of physiological saline, and CO gas was introduced for 15 minutes, followed by addition of an appropriate amount of [ alpha ], [ beta ] -potassium sodium tartrate99mTc]NaTcO4The physiological saline solution of (1), the mixture is reacted at 80 ℃ for 30 minutes, cooled to room temperature, and then the solution is acidified with 0.05mol/L HCl to pH 7-8 to give a solution99mTc][Tc(CO)3(H2O)3]+An intermediate solution;
(3)[99mTc]Tc(CO)3-L3preparation of the Complex
To the [2 ] prepared in step (2)99mTc][Tc(CO)3(H2O)3]+1mg of L prepared in step (1) was added to the solution3(dissolved in 1ml of a 0.05M sodium acetate solution having a pH of 5), and the reaction mixture was heated at 95 ℃ for 30 minutes to give [ alpha ], [ solution ] of sodium acetate99mTc]Tc(CO)3-L3A possible structure of the complex is as follows:
Figure BDA0001924802980000161
as shown in FIG. 2, is the product of the preparation of example 2 of the present invention99mTc]Tc(CO)3-L3The analysis result shows that: the product had only one structure and a retention time of 13.7 minutes; the radiochemical purity of the product is more than 95 percent.
Example 3
Re(CO)3-L2Preparation of the Complex
10ml of an aqueous solution of rhenium pentacarbonyl bromide (80mg, 0.2mmol) were refluxed at 105 ℃ for 24 hours, after which L from example 1 was added2(30mg, 0.038mmol) was added to a solution containing Re (CO)3(H2O)3To the above reaction solution of Br intermediate (2mL), the mixture was acidified with 0.1N HCl to pH 5 and heated at 95 ℃ for 3 hours to give re (co)3-L2A complex; the possible structure is as follows, as shown in FIG. 3, Re (CO) prepared in example 3 of the present invention3-L2Ultraviolet liquid chromatography analysis chart of (1). The analysis result shows that: the product only has one structure, and the existence of a splitting peak indicates that chiral isomers exist in the complex structure.
Figure BDA0001924802980000162
Example 4
Re(CO)3-L3Preparation of the Complex
10ml of an aqueous solution of rhenium pentacarbonyl bromide (80mg, 0.2mmol) were refluxed at 105 ℃ for 24 hours, after which L from example 2 was added3(50mg, 0.038mmol) was added to a solution containing Re (CO)3(H2O)3To the above reaction solution of Br intermediate (2mL), the mixture was acidified with 0.1N HCl to pH 5 and heated at 95 ℃ for 3 hours to give re (co)3-L3A complex; the possible structure is as follows: as shown in FIG. 4, Re (CO) prepared in example 4 of the present invention3-L3Ultraviolet liquid chromatography analysis chart of the complex.
Figure BDA0001924802980000171
Example 5
[99mTc]Tc(CO)3-L4Preparation of the Complex
(1)L4Synthesis of (2)
1) Synthesis of BN peptides
BN peptide (H) synthesized using standard Fmoc-peptide chemistry on Rink amide, 4-methyl-benzhydrylamine resin (200-2N (amino) -PEG2(Dipolyethylene glycol) - [ D-Tyr6，βAla11，Thi13，Nle14]BN)
For amino acid (D-Tyr)6β Ala11, Thi13, Nle14) using the general formula below, with amino acids/O-benzotriazol-tetramethyluronium Hexafluorophosphate (HBTU)/DIPEA (4.0: 3.9: 4.0 equiv., 30 min, reaction at room temperature), Fmoc (fluorenylmethyloxycarbonyl) -8-amino-3, 6-dioxaoctanoic acid was finally added, the same procedure as above was followed, after which the product was deprotected using 50% piperidine and DMF, the resin was dried, TFA/TIPS/H was used2Cleavage of the peptide with a mixture of O (95: 2.5: 2.5, v/v/v), recrystallization from ether, purification by semi-preparative HPLC (retention time: 5.9min, B% of 8-60: 10min, flow rate 6mL/min) gave BN peptide (42% in overall yield, 0.95 equiv, 0.023mmol, 29.5 mg); identifying the product by mass spectrometry: m/z 1285.6[ M + H ]]+；C61H85N15O14S; calculated values: 1284.5.
2) synthesis of glutamic acid-urea-lysine
The synthetic route of the glutamic acid-urea-lysine is shown in the following figure;
tert-butyl protected glutamic acid 14(3 equiv.) with triphosgene (1 equiv., 1mmol) and DIPEA (3.0mL) in CH2Cl2Isocyanate 15 reacted in (150mL) to give glutamic acid; isocyanate 15 of glutamic acid was immobilized with resin (2-chloro-trityl resin, 0.540g, 0.9mmol) with 3.0mmol of Fmoc-Lys (alloc) -OH under mild stirring (16 hours, room temperature) to give product 16; then, the reaction solution is reacted with Pd (PPh) at room temperature3) (7.2mM) and morpholine (1.5mM) to cleave the allyloxycarbonyl protecting group therein to provide product 17; the solvent was changed to DMF and the resin was washed with 1% DIPEA in DMF and sodium diethyldithiocarbamate trihydrate solution (10mL, 0.07M); then, with TFA/TIPS/H2O (95: 2.5: 2.5, v/v/v) cleavage of product 17 followed by purification by RP-HPLC with the following gradient: A-B, 0-60% B for 6 min, then 100% B for 1 min (A is H with 0.1% TFA)2O solution, B is CH with 0.1% TFA3CN solution; the retention time was: 6.2 minutes; flow rate of 6 mL/min); the final product 18 (glutamic acid-urea-lysine) was obtained in 30% overall yield, ms spectrum: m/z 320.1[ M + H ]]+；C12H21N3O7(ii) a Calculated values: 319.3;
Figure BDA0001924802980000181
3) dual activated (HBED-CC) TFP2Synthesis of (2)
Same as in example 2;
1-fold equivalent of BD peptide and 0.91 equivalent of dual activated (HBED-CC) TFP2In 1.0ml of DMF containing 2 times equivalent of DIPEA (0.044mmol) dissolved therein to obtain HBED-CCTFP-ester substituted by BN peptide, and reacting the ester with excess glutamic acid-urea-lysine 18(10 equivalent, 16 hours, room temperature) to obtain Fe-protected target ligand L4(HBED-CC chelator) after which the iron complexes were isolated by semi-preparative HPLC, in order to remove iron from the corresponding HBED-CC chelator, the following procedure was followed: 1) fe protected target ligand L4Trapped on a solid phase extraction column (C-18, Classic Short)WAT051910, Waters corporation, usa); 2) the solid phase extraction column was washed with 1M hydrochloric acid (2.0mL, Waters, USA), then with H2O (2mL, ultra pure, Waters corporation, USA) to remove iron; 3) eluting with 70:30(v/v, 5.0mL) acetonitrile/water solution from the column to obtain ligand L4The structure is as follows:
Figure BDA0001924802980000191
identification of compounds by mass spectrometry: m/z: 2100.5[ M + H]+；C99H134N20O29S, calculating a value: 2100.3, respectively;
(2)[99mTc][Tc(CO)3(H2O)3]+preparation of intermediate solutions
4mg of Na2CO35.6mg of NaBH4And 20mg of potassium sodium tartrate were dissolved in 1mL of physiological saline, and CO gas was introduced for 15 minutes, followed by addition of an appropriate amount of [ alpha ], [ beta ] -potassium sodium tartrate99mTc]NaTcO4The physiological saline solution of (1), the mixture is reacted at 80 ℃ for 30 minutes, cooled to room temperature, and then the solution is acidified with 0.05mol/L HCl to pH 7-8 to give a solution99mTc][Tc(CO)3(H2O)3]+An intermediate solution;
(3)[99mTc]Tc(CO)3-L4preparation of the Complex
To the [2 ] prepared in step (2)99mTc][Tc(CO)3(H2O)3]+To the solution was added 1mg of L4(dissolved in 1ml of a 0.05M sodium acetate solution having a pH of 5), and the reaction mixture was heated at 95 ℃ for 30 minutes to give [ alpha ], [ solution ] of sodium acetate99mTc]Tc(CO)3-L4A possible structure of the complex is as follows:
Figure BDA0001924802980000192
wherein the content of the first and second substances,
Figure BDA0001924802980000193
as shown in FIG. 5, is the product of example 5 of the present invention99mTc]Tc(CO)3-L4The radiochemical purity of the product is more than 95 percent according to the radioactive liquid chromatographic analysis chart of the complex.
Example 6
[99mTc]Tc(CO)3-L1Preparation of the complex:
(1) ligand L1Synthesis of (2)
Compound 7(433.8mg, 0.673mmol) was dissolved in 10mL TFA, stirred at room temperature for 4h, the solvent removed under reduced pressure and purified by preparative HPLC to give product 1 (L)1) The yield is 59.8%;
1H NMR(400MHz，D2o) δ: 7.17-7.14(m, 4H, J ═ 1.2Hz), 7.09(d, 2H, J ═ 4Hz), 4.27(s,4H), 3.78(s,4H), 3.61-3.55(m, 4H, J ═ 2.4)2.76(t, 4H, J ═ 1.6), 2.56(t, 4H, J ═ 1.6), HRMS mass spectrometry C26H32N2O10：[M+H]+M/z: 533.2 calculated as 533.2;
(2)[99mTc][Tc(CO)3(H2O)3]+preparation of intermediate solutions
4mg of Na2CO35.6mg of NaBH4And 20mg of potassium sodium tartrate were dissolved in 1mL of physiological saline, and CO gas was introduced for 15 minutes, followed by addition of an appropriate amount of [ alpha ], [ beta ] -potassium sodium tartrate99mTc]NaTcO4The physiological saline solution of (1), the mixture is reacted at 80 ℃ for 30 minutes, cooled to room temperature, and then the solution is acidified with 0.05mol/L HCl to pH 7-8 to give a solution99mTc][Tc(CO)3(H2O)3]+An intermediate solution;
(3)[99mTc]Tc(CO)3-L1preparation of the Complex
To the [2 ] prepared in step (2)99mTc][Tc(CO)3(H2O)3]+1mg of L prepared in step (1) was added to the solution1(0.05M in 1ml, pH ═5 in a sodium acetate solution) at 95 ℃ for 30 minutes to obtain [2 ], [99mTc]Tc(CO)3-L1And (3) a complex.
As shown in FIG. 6, is the product of the present invention prepared in example 6 of the present invention99mTc]Tc(CO)3-L1The results of the radioactive liquid chromatography analysis of the complex showed the presence of two structures (one for each peak) for the product, corresponding to two retention times (12.0 min and 13.2 min). The peaks of the two components are split peaks, indicating the presence of chiral isomers in the complex structure.
Example 7
[99mTc]Tc(CO)3Preparation of the PSMA-11 Complex:
(1)[99mTc][Tc(CO)3(H2O)3]+preparation of intermediate solutions
4mg of Na2CO35.6mg of NaBH4And 20mg of potassium sodium tartrate were dissolved in 1mL of physiological saline, and CO gas was introduced for 15 minutes, followed by addition of an appropriate amount of [ alpha ], [ beta ] -potassium sodium tartrate99mTc]NaTcO4The physiological saline solution of (1), the mixture is reacted at 80 ℃ for 30 minutes, cooled to room temperature, and then the solution is acidified with 0.05mol/L HCl to pH 7-8 to give a solution99mTc][Tc(CO)3(H2O)3]+An intermediate solution;
(2)[99mTc]Tc(CO)3preparation of (E) -PSMA-11 Complex
The term "prepared in step (1)99mTc][Tc(CO)3(H2O)3]+To the solution was added 1mg of PSMA-11 (glutamic acid-urea-lysine, available from ABXGmbh, Germany, cat # 9919) (dissolved in 1ml of a 0.05M sodium acetate solution having a pH of 5), and the reaction mixture was heated at 95 ℃ for 30 minutes to give99mTc]Tc(CO)3-a PSMA-11 complex.
As shown in FIG. 7, is the product of example 7 of the present invention99mTc]Tc(CO)3And (3) a radioactive liquid chromatography analysis chart of the PSMA-11 complex, wherein the analysis result shows that a plurality of groups of peaks indicate that the product has a plurality of isomers.
The present inventors have previously attempted to use different types of technetium core TcOs3+Labeling HBED-CC does not yield ideal results, mainly because these technetium cores require 4-5 coordinating atoms to form stable complexes with ligands, whereas HBED-CC has difficulty in providing 4-5 spatially close coordinating atoms to participate in coordination without creating a large molecular tension; in addition, the use of metal reducing agents in labeling is also a limiting factor; for example, the formation of technetium-oxygen core requires the use of stannous chloride as a reducing agent, and studies have found that stannous atoms can form stable complexes with HBED-CC, which inhibits the coordination of ligands to the technetium core.
Through experiments, the inventor unexpectedly found that HBED-CC can be labeled with technetium carbonyl, which may be analyzed as follows: 1. the reducing agent used in the reaction is a non-metallic reducing agent sodium borohydride; HBED-CC has a plurality of N, O atoms capable of participating in coordination, which can form a stable complex with technetium carbonyl by only providing 2-3 coordination sites, and the larger molecular structure of HBED-CC can not generate large steric hindrance on coordination, so that higher activation energy is not needed for realizing the coordination reaction; meanwhile, because the HBED-CC has a larger molecular structure, when a targeting group (small molecule or polypeptide) is coupled with a ligand through an amido bond, the targeting group can keep a large spatial degree of freedom and is not limited by the coordination with a technetium core, so that the influence of the coordination on the affinity of a target spot is weakened.
The inventor finds that the molecular structure of HBED-CC is complex, a plurality of sites for the coordination of technetium carbonyl are arranged in the molecular structure, and the difficulty of the sites participating in the coordination is greatly influenced by factors such as the acidity and alkalinity of a reaction solution, so that the control of reaction conditions has a decisive influence on the reaction product.
And the coordination constant of metal gallium and HBED-CC is very high (38.5), and a very stable complex can be formed at normal temperature. This is the difficulty in labeling HBED-CC with technetium-99 m compared to gallium-68.
The present inventors used a model compound (L) containing HBED-CC bifunctional linker in the early stages of the experiment1) With technetium carbonylPerforming coordination, and finding that the HPLC analysis result of the product has multiple peaks, namely the product has coordination isomers; however, the properties of the drugs with different structures, such as drug efficacy, metabolism, etc., in vivo also have certain differences, which requires research one by one in the evaluation process of the radiopharmaceuticals.
The inventor selects HBED-CC derivative PSMA-11 with substituent groups for carbonyl technetium labeling, and the experimental result shows that the HPLC analysis result of the product has 4 to 5 multi-peaks. In view of the above experimental results, the present inventors have analyzed that HBED-CC has multiple sites to which technetium carbonyl can coordinate, and therefore, the product obtained by coordinating HBED-CC with technetium carbonyl is of a non-unitary structure.
In order to obtain a product with a single structure, the inventor designs and synthesizes ligands L2, L3 and L4 which are not substituted by-OH in R1 and R2, and optimizes experimental conditions: the pH value, the reaction temperature and the amount of the labeled precursor of the reaction solution are changed, and a single peak is shown in an HPLC analysis spectrogram of the final product, so that the structure of the final product is clearer, and the design requirement of the radiopharmaceutical is better met.

Claims (3)

1. A complex of a bifunctional linker coordinated to a metal carbonyl core having the formula:
Figure FDA0002790970140000011
or
Figure FDA0002790970140000012
Or
Figure FDA0002790970140000013
Or
Figure FDA0002790970140000021
Or
Figure FDA0002790970140000022
Wherein the content of the first and second substances,
Figure FDA0002790970140000023
2. a method of preparing a complex of a technetium carbonyl core-tagged bifunctional linker as defined in claim 1, comprising the steps of:
(1) preparation of N, N '-bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N' -diacetic acid containing substituent groups
Adding BF to methanol solution of 3- (4-hydroxyphenyl) propionic acid3·Et2O, stirring at room temperature, removing the solvent, and purifying by flash chromatography to obtain a methylated product, namely methyl 3- (4-hydroxyphenyl) propionate;
adding MgCl into 3- (4-hydroxyphenyl) methyl propionate in acetonitrile2Paraformaldehyde and triethylamine, heating and refluxing the mixture, diluting with water, acidifying with hydrochloric acid, extracting with diethyl ether, and collecting the organic layer with MgSO4Drying and filtering, concentrating the filtrate, and purifying the residue by flash chromatography to give methyl 3- (3-formyl-4-hydroxyphenyl) propionate;
adding ethylenediamine into 3- (3-formyl-4-hydroxyphenyl) methyl propionate dissolved in MeOH at room temperature, stirring overnight at 50 ℃, cooling the bis-Schiff base obtained by condensation reaction in ice bath, and adding NaBH in batches4And stirred at room temperature overnight, the mixture was extracted with ethyl acetate, and the organic layer was then extracted with MgSO4Drying, filtering, concentrating the filtrate and purifying the resulting residue by flash chromatography to give 3,3' - ((((ethane-1, 2-diylbis (azenediyl)) bis-dimethyl (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate;
in 3,3' - (((ethane-1, 2-diylbis (aza-N-phenyl))Diyl)) bis-dimethyl (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate in acetonitrile was added tert-butyl bromoacetate and Na2CO3Then the mixture is heated at 60 ℃, overnight, cooled to room temperature and filtered, the filtrate is concentrated and the residue is purified by flash chromatography to give 3,3' - (((2,2,13, 13-tetramethyl-4, 11-dioxo-3, 12-) dimethyldioxa-6, 9-diazatetetradecane-6, 9-diyl) di (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate;
a methanol/sodium hydroxide (1N) (1/1) solution of 3,3' - (((2,2,13, 13-tetramethyl-4, 11-dioxo-3, 12-) dimethyldioxa-6, 9-diazatetradecane-6, 9-diyl) di (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate was stirred at room temperature to remove the methyl group, then hydrochloric acid was added to the reaction mixture to adjust the pH to 4-5, the resulting mixture was extracted with EtOAc, and then the organic layer was extracted with MgSO 44Drying and filtering, concentrating the filtrate to obtain a residue which is purified by flash chromatography to obtain 3,3' - ((((2, 2,13, 13-tetramethyl-4, 11-dioxo-3, 12-dioxa-6, 9-diazacyclotetradecane-6, 9-diyl) di (methylene)) di (4-hydroxy-3, 1-phenylene)) dipropionate;
then, N ' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N ' -diacetic acid containing a substituent group was prepared separately from 3,3' - ((((2, 2,13,13 tetramethyl-4, 11-dioxo-3, 12-dioxa-6, 9-diazacyclotetradecane-6, 9-diyl) di (methylene)) di (4-hydroxy-3, 1-phenylene)) dipropionate;
(2)[99mTc][Tc(CO)3(H2O)3]+preparation of intermediate solutions
The reaction ratio of Na2CO3，NaBH4And sodium potassium tartrate are dissolved in the brine, CO gas is introduced, and then an appropriate amount of [ alpha ], [ alpha ] is added99mTc]NaTcO4The physiological saline solution of (1), reacting the mixture at 60 to 90 ℃, cooling to room temperature, and then acidifying the solution to pH 7 to 8 to obtain the product99mTc][Tc(CO)3(H2O)3]+An intermediate solution;
(3) preparation of carbonyl technetium nuclear labeling complex of N, N '-bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N' -diacetic acid containing substituent group
To the [2 ] prepared in step (2)99mTc][Tc(CO)3(H2O)3]+Respectively adding proper amount of the N, N' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl group containing the substituent group prepared in the step (1) into the intermediate solution]Heating the reaction mixture to obtain N, N' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl containing substituent groups]Carbonyl technetium nuclear labeling coordination compound of ethylenediamine-N, N' -diacetic acid;
the structure of the substituted group-containing N, N '-bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N' -diacetic acid in the step (1) is as follows:
Figure FDA0002790970140000041
the above-mentioned
Figure FDA0002790970140000042
Or, the said
Figure FDA0002790970140000043
Or, the said
Figure FDA0002790970140000044
Figure FDA0002790970140000045
3. A method for preparing a complex of a rhenium carbonyl core-tagged bifunctional linker as defined in claim 1, comprising the steps of:
(1) preparation of N, N '-bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N' -diacetic acid containing substituent groups
Adding BF to methanol solution of 3- (4-hydroxyphenyl) propionic acid3·Et2O, stirring at room temperature, removing the solvent, and purifying by flash chromatography to obtain a methylated product, namely methyl 3- (4-hydroxyphenyl) propionate;
adding MgCl into 3- (4-hydroxyphenyl) methyl propionate in acetonitrile2Paraformaldehyde and triethylamine, heating and refluxing the mixture, diluting with water, acidifying with hydrochloric acid, extracting with diethyl ether, and collecting the organic layer with MgSO4Drying and filtering, concentrating the filtrate, and purifying the residue by flash chromatography to give methyl 3- (3-formyl-4-hydroxyphenyl) propionate;
adding ethylenediamine into 3- (3-formyl-4-hydroxyphenyl) methyl propionate dissolved in MeOH at room temperature, stirring overnight at 50 ℃, cooling the bis-Schiff base obtained by condensation reaction in ice bath, and adding NaBH in batches4And stirred at room temperature overnight, the mixture was extracted with ethyl acetate, and the organic layer was then extracted with MgSO4Drying, filtering, concentrating the filtrate and purifying the resulting residue by flash chromatography to give 3,3' - ((((ethane-1, 2-diylbis (azenediyl)) bis-dimethyl (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate;
to a solution of 3,3' - (((ethane-1, 2-diylbis (azenediyl)) bis-dimethyl (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate in acetonitrile was added tert-butyl bromoacetate and Na2CO3Then the mixture is heated at 60 ℃, overnight, cooled to room temperature and filtered, the filtrate is concentrated and the residue is purified by flash chromatography to give 3,3' - (((2,2,13, 13-tetramethyl-4, 11-dioxo-3, 12-) dimethyldioxa-6, 9-diazatetetradecane-6, 9-diyl) di (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate;
a methanol/sodium hydroxide (1N) (1/1) solution of 3,3' - (((2,2,13, 13-tetramethyl-4, 11-dioxo-3, 12-) dimethyldioxa-6, 9-diazatetradecane-6, 9-diyl) di (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate was stirred at room temperature to remove the methyl group, then hydrochloric acid was added to the reaction mixture to adjust the pH to 4-5, the resulting mixture was extracted with EtOAc, and then the organic layer was extracted with MgSO 44Drying and filtering, concentrating the filtrate to obtain a residue, and purifying the residue by flash chromatography to obtain 3,3' - (((2,2,13,13 tetramethyl) 2Phenyl-4, 11-dioxo-3, 12-dioxa-6, 9-diazacyclotetradecane-6, 9-diyl) di (methylene)) bis (4-hydroxy-3, 1-phenylene)) dipropionate;
then, N ' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N ' -diacetic acid containing a substituent group was prepared separately from 3,3' - ((((2, 2,13,13 tetramethyl-4, 11-dioxo-3, 12-dioxa-6, 9-diazacyclotetradecane-6, 9-diyl) di (methylene)) di (4-hydroxy-3, 1-phenylene)) dipropionate;
(2) refluxing under water solution of rhenium pentacarbonyl bromide, and then carrying out the N, N' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl group containing the substituent group prepared in the step (1)]ethylenediamine-N, N' -diacetic acid to a solution containing Re (CO)3(H2O)3In the reaction solution of the Br intermediate, the mixture was acidified to pH 4 to 6, and heated to obtain N, N' -bis [ 2-hydroxy-5- (carboxyethyl) benzyl group having a substituent group]A rhenium carbonyl core labeling complex of ethylenediamine-N, N' -diacetic acid;
the structure of the substituted group-containing N, N '-bis [ 2-hydroxy-5- (carboxyethyl) benzyl ] ethylenediamine-N, N' -diacetic acid in the step (1) is as follows:
Figure FDA0002790970140000061
the above-mentioned
Figure FDA0002790970140000062
Or, the said
Figure FDA0002790970140000063
Alternatively, the first and second electrodes may be,
Figure FDA0002790970140000064
CN201811611294.6A 2018-12-27 2018-12-27 Complex of bifunctional linking agent coordinated with carbonyl metal core and preparation method thereof Active CN109438517B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811611294.6A CN109438517B (en) 2018-12-27 2018-12-27 Complex of bifunctional linking agent coordinated with carbonyl metal core and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811611294.6A CN109438517B (en) 2018-12-27 2018-12-27 Complex of bifunctional linking agent coordinated with carbonyl metal core and preparation method thereof

Publications (2)

Publication Number Publication Date
CN109438517A CN109438517A (en) 2019-03-08
CN109438517B true CN109438517B (en) 2021-01-08

Family

ID=65538283

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811611294.6A Active CN109438517B (en) 2018-12-27 2018-12-27 Complex of bifunctional linking agent coordinated with carbonyl metal core and preparation method thereof

Country Status (1)

Country Link
CN (1) CN109438517B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110144471B (en) * 2019-05-15 2020-10-09 中国原子能科学研究院 Method for extracting technetium from nuclear fuel post-treatment waste liquid
CN112358422B (en) * 2020-10-16 2023-06-23 中国辐射防护研究院 Preparation method of novel chelating agent NBED
CN114436905A (en) * 2022-01-24 2022-05-06 攀枝花学院 Purification method of 3-aldehyde-4-hydroxy methyl phenylacetate
CN115572320B (en) * 2022-09-09 2023-09-12 中南大学湘雅医院 Prostate cancer molecular probe and preparation method and application thereof
CN116550006B (en) * 2023-07-07 2023-11-10 上海奥浦迈生物科技股份有限公司 Formula, preparation method and application of chromatographic combination liquid

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016663A1 (en) * 1993-12-16 1995-06-22 Ciba-Geigy Ag N,n'-bis(2-hydroxybenzyl)ethylenediamine-n,n'-diacetic acid derivatives as chelating agents
CN101709060A (en) * 2009-12-02 2010-05-19 北京师范大学 F-triazole ring-polyethylene glycol-metronidazole compound and preparation method thereof
CN102603647A (en) * 2012-03-22 2012-07-25 北京师范大学 18/19F-ester nitroimidazole compound, preparation method thereof and application as hypoxic tissue developing agent
EP3064224A1 (en) * 2015-03-03 2016-09-07 Isotopia Molecular Imaging Ltd Method for labeling a prostate-specific membrane antigen ligand with a radioactive isotope
CN107847618A (en) * 2015-07-07 2018-03-27 五制药股份有限公司 HBED diphosphonates/ester, its radiate metal conjugate and they as treat diagnosticum purposes
CN108541302A (en) * 2015-12-31 2018-09-14 五制药股份有限公司 Urea base prostate-specific membrane antigen (PSMA) inhibitor for being imaged and treating

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10406246B2 (en) * 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016663A1 (en) * 1993-12-16 1995-06-22 Ciba-Geigy Ag N,n'-bis(2-hydroxybenzyl)ethylenediamine-n,n'-diacetic acid derivatives as chelating agents
CN101709060A (en) * 2009-12-02 2010-05-19 北京师范大学 F-triazole ring-polyethylene glycol-metronidazole compound and preparation method thereof
CN102603647A (en) * 2012-03-22 2012-07-25 北京师范大学 18/19F-ester nitroimidazole compound, preparation method thereof and application as hypoxic tissue developing agent
EP3064224A1 (en) * 2015-03-03 2016-09-07 Isotopia Molecular Imaging Ltd Method for labeling a prostate-specific membrane antigen ligand with a radioactive isotope
CN107847618A (en) * 2015-07-07 2018-03-27 五制药股份有限公司 HBED diphosphonates/ester, its radiate metal conjugate and they as treat diagnosticum purposes
CN108541302A (en) * 2015-12-31 2018-09-14 五制药股份有限公司 Urea base prostate-specific membrane antigen (PSMA) inhibitor for being imaged and treating

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
68Ga-Chelation and comparative evaluation of N,N′-bis-[2-hydroxy-5-(carboxyethyl)benzyl]-ethylenediamine-N,N′-diacetic acid (HBED-CC) conjugated NGR and RGD peptides as tumor targeted molecular imaging probes;Drishty Satpati等，;《Med. Chem. Commun.》;20170216;全文 *
Monomeric and Dimeric 68Ga-Labeled Bombesin Analogues for Positron Emission Tomography (PET) Imaging of Tumors Expressing Gastrin-Releasing Peptide Receptors (GRPrs);Christos Liolios等，;《J. Med. Chem.》;20180212;第61卷;全文 *

Also Published As

Publication number Publication date
CN109438517A (en) 2019-03-08

Similar Documents

Publication Publication Date Title
CN109438517B (en) Complex of bifunctional linking agent coordinated with carbonyl metal core and preparation method thereof
US10960089B2 (en) Radiolabeled drug
JP6164556B2 (en) Drug for producing radiolabeled polypeptide with reduced nonspecific renal accumulation
US10646598B2 (en) Cage-like bifunctional chelators, copper-64 radiopharmaceuticals and PET imaging using the same
WO2019065774A1 (en) Radioactive drug
EP3212610B1 (en) Methods for low temperature fluorine-18 radiolabeling of biomolecules
CN115286697B (en) Dual-targeting compound and preparation method and application thereof
JP2014515729A (en) New PET tracer
Shetty et al. Synthesis of novel 68Ga-labeled amino acid derivatives for positron emission tomography of cancer cells
KR20050033067A (en) Radioactively labelled amino acid analogues, their preparation and use
JP5318874B2 (en) Radiofluorination method
CN112625065A (en) Technetium-99 m marked FAPI (FAPI) derivative containing hydrazino nicotinamide and archaea, and preparation method and application thereof
CN115260160B (en) Compound of targeted fibroblast activation protein FAP, preparation method and application thereof
EP2150514B1 (en) 18f-labelled folates
JP6410339B2 (en) Radionuclide labeled octreotide derivatives
Mushtaq et al. Efficient 125 I-radiolabeling of biomolecules using a strain-promoted oxidation-controlled cyclooctyne–1, 2-quinone cycloaddition reaction
PL239934B1 (en) Derivatives of PSMA inhibitors for ⁹⁹ᵐTc labelling by HYNIC, radiopharmaceutical kit, radiopharmaceutical preparations and their use in the diagnosis of prostate cancer
Davis et al. Fully automated peptide radiolabeling from [18 F] fluoride
WO2023019303A1 (en) Radiopharmaceuticals, methods for the production thereof, and uses in treatment, diagnosis and imaging diseases
Gniazdowska et al. Synthesis, radiochemistry and stability of the conjugates of technetium-99m complexes with Substance P
CN115974962A (en) FAP (FAP-associated protein) targeted probe as well as preparation method and application thereof
WO2024021556A1 (en) Radioactive metal complex targeting prostate specific membrane antigen and labeling ligand thereof
KR101743727B1 (en) PEG and DOTA - containing RGD derivatives, a process for the preparation thereof and a PET contrast agent comprising the same
Hirata et al. Synthesis and evaluation of a multifunctional probe with a high affinity for prostate-specific membrane antigen (PSMA) and bone
CN115368342B (en) Fibroblast active protein inhibitor, radionuclide marker, preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant